Artelo biosciences completes enrollment of the first three cohorts in its cares study evaluating art27.13 for the treatment of cancer-related anorexia and weight loss

Initiates fourth cohort at a 650-microgram dose with data expected in q4 2022 initiates fourth cohort at a 650-microgram dose with data expected in q4 2022
ARTL Ratings Summary
ARTL Quant Ranking